Early access to medicines scheme (EAMS) scientific opinion: Nivolumab for treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal cancer after prior chemotherapy

Positive scientific opinion based on study (n=419) which showed that after 12 months, overall survival was 47% in nivolumab group vs. 34% in chemotherapy arm (paclitaxel or docetaxel). After 18 months, these proportions were 31% and 21%, respectively.

Medicines and Healthcare products Regulatory Agency